Jefferies Initiates Coverage On Phathom Pharmaceuticals with Buy Rating, Announces $32 Price Target

Jefferies initiates coverage on Phathom Pharmaceuticals (NASDAQ:PHAT) with a Buy rating and a $32 price target.

Benzinga · 11/19/2019 11:31

Jefferies initiates coverage on Phathom Pharmaceuticals (NASDAQ:PHAT) with a Buy rating and a $32 price target.